Department of Respiratory Medicine, Medical School of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
Department of Anaesthesiology, Medical School of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
Respiration. 2020;99(9):789-799. doi: 10.1159/000509761. Epub 2020 Nov 18.
Medical thoracoscopy is the gold standard for the diagnosis of pleural diseases. To date, no consensus exists regarding the choice of sedative and analgesic agents in patients undergoing local anesthetic thoracoscopy (LAT), and questions are raised as to whether sedatives may add to respiratory side effects.
The aim of the study was to test the hypothesis that administration of midazolam associated with lidocaine versus lidocaine alone in patients with LAT adds to respiratory side effects.
We randomly assigned 80 patients to a 1:1 study to 2 groups: local anesthesia by lidocaine (n = 40) versus lidocaine and midazolam (n = 40), with the primary end point being the mean lowest oxygen saturation. The secondary end points were cardiovascular parameters, complications, days of drainage, hospital stay, and patients' quality of life (QoL) as assessed by a visual analog scale (VAS).
The mean age of all patients was 66.6 ± 13.1 years. The study comprised 50 males (62.5%). No difference was observed in the demographics between the 2 groups. No significant difference was observed between the 2 groups in oxygen saturation (primary end point). A significant difference was observed in favor of the midazolam group regarding the QoL assessed by VAS.
Midazolam does not add to respiratory side effects when it is used with lidocaine for LAT, while patients' QoL is actually improved in this group. Therefore, in our department, we changed our startegy in favor of the association of lidocaine and midazolam.
胸腔镜检查是胸膜疾病诊断的金标准。迄今为止,对于接受局部麻醉性胸腔镜检查(LAT)的患者选择镇静和镇痛药物尚无共识,并且人们质疑镇静剂是否会增加呼吸副作用。
本研究旨在检验以下假设,即在 LAT 中使用咪达唑仑与利多卡因联合给药与单独使用利多卡因相比,会增加呼吸副作用。
我们将 80 名患者随机分为 1:1 研究的 2 组:利多卡因局部麻醉(n = 40)与利多卡因和咪达唑仑(n = 40),主要终点是平均最低血氧饱和度。次要终点是心血管参数,并发症,引流天数,住院时间以及通过视觉模拟量表(VAS)评估的患者生活质量(QoL)。
所有患者的平均年龄为 66.6 ± 13.1 岁。该研究包括 50 名男性(62.5%)。两组之间的人口统计学数据无差异。两组之间的血氧饱和度(主要终点)无显着差异。在使用 VAS 评估 QoL 时,咪达唑仑组具有明显的优势。
在 LAT 中使用利多卡因加用咪达唑仑不会增加呼吸副作用,而实际上,该组患者的 QoL 得到了改善。因此,在我们科室,我们改变了策略,转而支持利多卡因和咪达唑仑的联合应用。